Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Nateraâs complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications. Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Companyâs own robust laboratory processes thousands of genetic tests per month. Nateraâs goal is to transform the way people â both providers and patients â respond to and manage genetic diseases. Source
No articles found.
G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on th...
G1 Therapeutics, Inc., is a clinical-stage biop...
Progenics develops innovative medicines and other technologies to target and treat...
Progenics develops innovative medicines and oth...
Organovo is a biotech platform company that has developed a leadership position wi...
Organovo is a biotech platform company that has...
Cellectis is a clinical-stage biopharmaceutical company that harnesses the immune ...
Cellectis is a clinical-stage biopharmaceutical...
Medigus is a medical device company specializing in developing minimally invasive ...
Medigus is a medical device company specializin...
At GlycoMimetics, we are committed to helping to make a difference in the lives of...
At GlycoMimetics, we are committed to helping t...
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lu...
Biocept, Inc. is a molecular diagnostics compan...
Join the National Investor Network and get the latest information with your interests in mind.